Polymer Group seals Fiberweb acquisition

Polymer Group seals Fiberweb acquisition

NEWS Polymer Group seals Fiberweb acquisition Mann+Hummel invests in US operations P olymer Group Inc (PGI) has become the world’s largest manufac...

76KB Sizes 24 Downloads 126 Views

NEWS

Polymer Group seals Fiberweb acquisition

Mann+Hummel invests in US operations

P

olymer Group Inc (PGI) has become the world’s largest manufacturer of nonwovens after completing the acquisition of technical fabrics and filtration media specialist Fiberweb plc (see Filtration Industry Analyst, September 2013). As a result of the Fiberweb acquisition, PGI, which is owned by the Blackstone private equity group, now operates in 13 countries with approximately 4000 employees. Fiberweb’s products in filtration, building and construction, agriculture, healthcare, technical fabrics, geosynthetics and hygiene will complement PGI’s nonwovens for the hygiene, healthcare, wipes and industrial markets. “This is a milestone in our proud history and a critical moment for our industry,” said PGI chief executive officer (CEO) Joel Hackney. “PGI and Fiberweb are stronger together, and we are now well-positioned to deliver on the industry’s growing demand for global scale, innovation and leadership.” “We are committed to investing and growing our presence in our key market segments as well as those in which Fiberweb operates,” said Hackney.

For further information, visit www.polymergroupinc. com, www.fiberweb.com and www.blackstone.com

M

ann+Hummel has announced a multi-million dollar investment and expansion in the United States. The German filtration company will establish the North American headquarters for its Automotive Aftermarket and Industrial Filtration, and Purolator Sales and Marketing divisions in Raleigh, North Carolina, investing more than US$15 million in its Raleigh and Fayetteville sites in North Carolina over the next two years. Mann+Hummel strengthened its position and market coverage in the United States earlier this year with the acquisition of full ownership of Purolator Filters LLC and the establishment of Mann+Hummel Purolator Filters (see Filtration Industry Analyst, March 2013). The automotive filtration specialist has also recently opened a new Innovation Center in Raleigh in partnership with North Carolina State University. The North Carolina Innovation Center will combine engineering, research, strategy and innovation. “Our aim is to focus on innovation, quality and speed,” said Manfred Wolf, president and general manager of Mann+Hummel’s Automotive and Industrial Business.

For further information, visit www.mann-hummel.com and www.purolatorautofilters.net

Exchange Rates against the US Dollar Date: 22.11.2013 Country Australia

Rate A$1.09

Country Netherlands

Austria

E0.74

Norway

Belgium

E0.74

Philippines

C$1.05

Canada

Rate E0.74 NOK6.06 Peso43.86

Singapore

S$1.25

China

CNY6.09

South Africa

R10.07

Denmark

DKK5.50

South Korea

KWn1061.69

Finland

E0.74

Spain

France

E0.74

Sweden

SEK6.58

Germany

E0.74

Switzerland

CHF0.91

Taiwan

T$29.60

Thailand

Bt31.82

India Italy Japan Malaysia

16

Filtration Industry Analyst

Rs62.86 E0.74 ¥101.29 Rt3.22

UK USA

E0.74

£0.62

Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Fax: +44 (0) 1865 843973 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Publisher: David Hopwood Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Prices: 1291 for all European countries & Iran US$1448 for all countries except Europe and Japan ¥171 700 for Japan (Prices valid until 31 December 2013) To subscribe send payment to the address above. Tel: +44 (0)1865 843687 or via www.filtrationindustryanalyst.com Subscriptions run for 12 months, from the date payment is received. Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/ or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Digitally Produced by Mayfield Press (Oxford) LImited 12976

US$1.00

November 2013